The Effectiveness of QEEG-Guided Neurofeedback in Patients with (OCD)

The Effectiveness of Adding QEEG-Guided Neurofeedback to SSRIs in Patients with Obsessive-Compulsive Disorder (OCD)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231021059781N1

Enrollment

Registered

2023-10-24

Start date

2024-02-20

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A disorder characterized by the presence of persistent and recurrent irrational thoughts (obsessions), resulting in marked anxiety and repetitive excessive behaviors (compulsions) as a way to try to decrease that anxiety.. Obsessive-compulsive disorder

Interventions

Intervention group: 30 patients with OCD who, in addition to SSRI drug treatment (fluoxetine 40-60 mg or its equivalent from another SSRI approved for OCD treatment), are treated with neurofeedback ba

Eligibility

Sex/Gender

All

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1- Age between 18 and 40 years.2- Diagnosis of OCD based on DSM-1V criteria by a psychiatrist.3- Y-BOCS test score > 16.4- Filling the informed consent form.5- Absence of other Axis 1 disorders, for example, schizophrenia, bipolar disorder, depression, etc., mental retardation, substance abuse or psychiatric disorders due to medical problems that require treatment (considering the high association of obsessive-compulsive disorder with depression mild and moderate depression is allowed to enter the plan)6- Absence of other treatment or use of cognitive therapy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Examining the level of obsession before and after the intervention in order to evaluate the effectiveness of the intervention using the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), examining the changes in brain waves related to the disease before and after the intervention using the Neuroguide software and every two weeks thereafter From the beginning of the intervention. Checking the improvement of cognitive functions such as maintaining attention, visual memory, working memory, attention shift and response inhibition by CANTAB software before and after the intervention and every two weeks after the intervention. Checking the level of anxiety and depression in two stages: Before and after the end of the intervention by Beck's anxiety and depression questionnaires. Timepoint: Illness before and after the intervention by and every two weeks after the start of the intervention. Method of measurement: (Y-BOCS)? NEUROGUID, CANTAB , BDI, BAI.;Yale Brown Obsessive-Compulsive Scale. Timepoint: the beginning and end of the study,. Method of measurement: Yale Brown Obsessive-Compulsive Scale (Y-BOCS).	—

Measure

Time frame

Examining the level of obsession before and after the intervention in order to evaluate the effectiveness of the intervention using the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), examining the changes in brain waves related to the disease before and after the intervention using the Neuroguide software and every two weeks thereafter From the beginning of the intervention. Checking the improvement of cognitive functions such as maintaining attention, visual memory, working memory, attention shift and response inhibition by CANTAB software before and after the intervention and every two weeks after the intervention. Checking the level of anxiety and depression in two stages: Before and after the end of the intervention by Beck's anxiety and depression questionnaires. Timepoint: Illness before and after the intervention by and every two weeks after the start of the intervention. Method of measurement: (Y-BOCS)? NEUROGUID, CANTAB , BDI, BAI.;Yale Brown Obsessive-Compulsive Scale. Timepoint: the beginning and end of the study,. Method of measurement: Yale Brown Obsessive-Compulsive Scale (Y-BOCS).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Talaei

Mashhad University of Medical Sciences

Talaeia@mums.ac.ir21 0051 37112540

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026